|
|
Previous Article | Table of Contents | Next Article 
Characterization of primitive subpopulations of normal and leukemic cells
present in the blood of patients with newly diagnosed as well as
established chronic myeloid leukemia
AL Petzer, CJ Eaves, PM Lansdorp, L Ponchio, MJ Barnett and AC Eaves
Terry Fox Laboratory, British Columbia Cancer Agency, Vancouver, Canada.
Elevated numbers of primitive Philadelphia chromosome-positive (Ph+)
progenitors, including long-term culture-initiating cells (LTC-IC) as well
as colony-forming cells (CFC), have been previously described in the blood
of patients with chronic myeloid leukemia (CML) in chronic phase with high
white blood cell counts. In the present study, which focused primarily on
an analysis of circulating progenitors present in such patients at
diagnosis, we discovered the frequent and occasionally exclusive presence
of circulating normal (Ph-) LTC-IC, often at levels above those seen for
LTC-IC in the blood of normal individuals. The presence of detectable
numbers of circulating Ph- LTC-IC was independent of the fact that the same
peripheral blood samples also contained elevated numbers of predominantly
or exclusively Ph+ CFC. Interestingly, both the Ph+ and Ph- LTC-IC in these
samples were CD34+CD71- and variably CD38- and Thy-1+, as previously
documented for LTC-IC in normal marrow. Thus, neither CD38 nor Thy-1
expression was useful for discriminating between Ph+ and Ph- LTC-IC in
mixed populations. Nevertheless, an association of these phenotypes with
LTC- IC function did allow highly enriched (> 5% pure) suspensions of
either Ph+ or Ph- LTC-IC to be obtained from selected samples of CML blood
in which the initial LTC-IC population was either predominantly Ph+ or Ph-
, respectively. These findings suggest that the mechanisms causing
mobilization of leukemic stem cells in untreated CML patients may affect
their normal counterparts. They also indicate a possible new source of
autologous cells for the support of intensive therapy of CML patients.
Finally, they provide a method for obtaining the most highly purified
populations of Ph+ LTC-IC described to date. This method should be useful
for further analyses of the molecular activities of these very primitive
neoplastic cells.
Volume 88,
Issue 6,
pp. 2162-2171,
09/15/1996
Copyright © 1996 by The American Society of Hematology

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
M. Mohty, E. Jourdan, N. B. Mami, N. Vey, G. Damaj, D. Blaise, D. Isnardon, D. Olive, and B. Gaugler
Imatinib and plasmacytoid dendritic cell function in patients with chronic myeloid leukemia
Blood,
June 15, 2004;
103(12):
4666 - 4668.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. W. N. Deininger and B. J. Druker
Specific Targeted Therapy of Chronic Myelogenous Leukemia with Imatinib
Pharmacol. Rev.,
September 1, 2003;
55(3):
401 - 423.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. W.N. Deininger, S. G. O'Brien, J. M. Ford, and B. J. Druker
Practical Management of Patients With Chronic Myeloid Leukemia Receiving Imatinib
J. Clin. Oncol.,
April 15, 2003;
21(8):
1637 - 1647.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. L. Holyoake, X. Jiang, H. G. Jorgensen, S. Graham, M. J. Alcorn, C. Laird, A. C. Eaves, and C. J. Eaves
Primitive quiescent leukemic cells from patients with chronic myeloid leukemia spontaneously initiate factor-independent growth in vitro in association with up-regulation of expression of interleukin-3
Blood,
February 1, 2001;
97(3):
720 - 728.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. H. Brummendorf, T. L. Holyoake, N. Rufer, M. J. Barnett, M. Schulzer, C. J. Eaves, A. C. Eaves, and P. M. Lansdorp
Prognostic implications of differences in telomere length between normal and malignant cells from patients with chronic myeloid leukemia measured by flow cytometry
Blood,
March 15, 2000;
95(6):
1883 - 1890.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Jiang, A. Lopez, T. Holyoake, A. Eaves, and C. Eaves
Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia
PNAS,
October 26, 1999;
96(22):
12804 - 12809.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Holyoake, X. Jiang, C. Eaves, and A. Eaves
Isolation of a Highly Quiescent Subpopulation of Primitive Leukemic Cells in Chronic Myeloid Leukemia
Blood,
September 15, 1999;
94(6):
2056 - 2064.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Carlo-Stella, E. Regazzi, G. Sammarelli, S. Colla, D. Garau, A. Gazit, B. Savoldo, D. Cilloni, A. Tabilio, A. Levitzki, et al.
Effects of the Tyrosine Kinase Inhibitor AG957 and an Anti-Fas Receptor Antibody on CD34+ Chronic Myelogenous Leukemia Progenitor Cells
Blood,
June 1, 1999;
93(11):
3973 - 3982.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. M. Carella, E. Lerma, M. T. Corsetti, A. Dejana, P. Basta, F. Vassallo, M. Abate, M. Soracco, F. Benvenuto, O. Figari, et al.
Autografting With Philadelphia Chromosome-Negative Mobilized Hematopoietic Progenitor Cells in Chronic Myelogenous Leukemia
Blood,
March 1, 1999;
93(5):
1534 - 1539.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.D. Cashman, C.J. Eaves, A.H. Sarris, and A.C. Eaves
MCP-1, not MIP-1alpha , Is the Endogenous Chemokine That Cooperates With TGF-beta to Inhibit the Cycling of Primitive Normal but not Leukemic (CML) Progenitors in Long-Term Human Marrow Cultures
Blood,
October 1, 1998;
92(7):
2338 - 2344.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.C.Y. Wang, T. Lapidot, J.D. Cashman, M. Doedens, L. Addy, D.R. Sutherland, R. Nayar, P. Laraya, M. Minden, A. Keating, et al.
High Level Engraftment of NOD/SCID Mice by Primitive Normal and Leukemic Hematopoietic Cells From Patients With Chronic Myeloid Leukemia in Chronic Phase
Blood,
April 1, 1998;
91(7):
2406 - 2414.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A.L. Petzer, C.J. Eaves, M.J. Barnett, and A.C. Eaves
Selective Expansion of Primitive Normal Hematopoietic Cells in Cytokine-Supplemented Cultures of Purified Cells From Patients With Chronic Myeloid Leukemia
Blood,
July 1, 1997;
90(1):
64 - 69.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|